Openbookopenbook
Equity
OCPNF
+0.0 · +0.00%
USD · PINK

Olympus Corporation(OCPNF) Stock Analysis | Healthcare

USD --+0.00%
Reward53Moderate
Risk10Low
75%Data
2.1% dividend yield
Defensive Anchor
Market Cap:10.63Bn
ⓘ
Reward Rating
53
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
10
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on OCPNF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for OCPNF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $48.18.

What is Olympus Corporation?

Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania.

OCPNF · Verdict

Moderate reward · low risk

OCPNF stands out on volatility and balance sheet, but watch the growth signal.

Based on 88% data coverage

OCPNF · Verdict

What’s working & what to watch

Strengths 5

  • Volatility95/100

    Top decile vs peers

  • Balance sheet93/100

    Interest covered 24.3×

  • Cash flow77/100

    13% free-cash-flow margin

  • Valuation69/100

    P/E 21.0× · PEG 3.61

  • Profitability68/100

    12% net margin · 11% ROE

Watchouts 1

  • Growth43/100

    Rev +4.7% CAGR · earnings +0.6%

Model-based scoring. For information only — not financial advice.

What is Olympus Corporation?

Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 10.63B, and a P/E ratio of 17.2x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (53)

The scoring profile indicates limited reward potential at this time, with valuation and profitability offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

GKOSLarge Cap / 10.9B market cap
Glaukos Corp
Compare
BIOLarge Cap / 10.2B market cap
Bio-Rad Laboratories Inc
Compare
CHEOFLarge Cap / 11.6B market cap
Cochlear Limited
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap10.63B
P/E Ratio17.2321
Dividend Yield2.10%
Beta0.237
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.